Morphogen-IX Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
1
- Latest Deal Type
-
M&A
- Investors
-
1
Morphogen-IX General Information
Description
Developer of bone morphogenetic protein receptors designed to offer treatment for pulmonary arterial hypertension. The company's receptors offer therapies that alleviate the symptoms of pulmonary arterial hypertension, enabling drug discovery professionals to ensure maximum capital efficiency without sacrificing quality.
Contact Information
Website
www.morphogen-ix.comCorporate Office
- Babraham Hall
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Corporate Office
- Babraham Hall
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Morphogen-IX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 23-Feb-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 18-Dec-2018 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 18-Jan-2016 | $2.2M | $2.2M | Completed | Startup | |
| 1. University Spin-Out | 15-Jul-2015 | Completed | Startup |
Morphogen-IX Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Morphogen-IX Comparisons
Industry
Financing
Details
Morphogen-IX Competitors (61)
One of Morphogen-IX’s 61 competitors is Endeavor BioMedicines, a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Endeavor BioMedicines | Venture Capital-Backed | San Diego, CA | ||||
| Apeptico | Formerly VC-backed | Vienna, Austria | ||||
| Aurum Biosciences | Venture Capital-Backed | Glasgow, United Kingdom | ||||
| PepGen | Formerly VC-backed | Boston, MA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX |
Morphogen-IX Signals
Morphogen-IX Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cambridge Enterprise Ventures | Venture Capital | Minority | ||
| Cambridge Innovation Capital | Venture Capital | Minority | ||
| Index Ventures | Venture Capital | Minority | ||
| Medicxi Ventures (UK) | Venture Capital | Minority |
Morphogen-IX FAQs
-
When was Morphogen-IX founded?
Morphogen-IX was founded in 2015.
-
Where is Morphogen-IX headquartered?
Morphogen-IX is headquartered in Cambridge, United Kingdom.
-
What is the size of Morphogen-IX?
Morphogen-IX has 1 total employees.
-
What industry is Morphogen-IX in?
Morphogen-IX’s primary industry is Drug Discovery.
-
Is Morphogen-IX a private or public company?
Morphogen-IX is a Private company.
-
What is Morphogen-IX’s current revenue?
The current revenue for Morphogen-IX is .
-
How much funding has Morphogen-IX raised over time?
Morphogen-IX has raised $25.6M.
-
Who are Morphogen-IX’s investors?
Cambridge Enterprise Ventures, Cambridge Innovation Capital, Index Ventures, and Medicxi Ventures (UK) have invested in Morphogen-IX.
-
Who are Morphogen-IX’s competitors?
Endeavor BioMedicines, Apeptico, Aurum Biosciences, PepGen, and Rein Therapeutics are some of the 61 competitors of Morphogen-IX.
-
When was Morphogen-IX acquired?
Morphogen-IX was acquired on 23-Feb-2021.
-
Who acquired Morphogen-IX?
Morphogen-IX was acquired by Centessa Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process